接受阿扎那韦治疗的患者使用质子泵抑制剂疗法：禁忌？ - Suppr | 超能文献

Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?

作者信息

Furtek Kari J, Crum Nancy F, Olson Patrick E, Wallace Mark R

出版信息

J Acquir Immune Defic Syndr. 2006 Mar;41(3):394-6. doi: 10.1097/01.qai.0000192002.23400.6e.

DOI:10.1097/01.qai.0000192002.23400.6e

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?接受阿扎那韦治疗的患者使用质子泵抑制剂疗法：禁忌？

J Acquir Immune Defic Syndr. 2006 Mar;41(3):394-6. doi: 10.1097/01.qai.0000192002.23400.6e.

2

Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir.在接受利托那韦增强型阿扎那韦治疗的HIV感染患者中，阿扎那韦与质子泵抑制剂之间缺乏相互作用。

J Acquir Immune Defic Syndr. 2006 Mar;41(3):393-4; author reply 394. doi: 10.1097/01.qai.0000197075.56397.a5.

3

Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.低剂量奥美拉唑（每日 20 毫克）对健康受试者中多剂量阿扎那韦利托那韦的药代动力学的影响。

J Clin Pharmacol. 2011 Mar;51(3):368-77. doi: 10.1177/0091270010367651. Epub 2010 May 10.

4

Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir.猫爪草与蛋白酶抑制剂阿扎那韦、利托那韦和沙奎那韦之间的相互作用。

Eur J Clin Pharmacol. 2008 Dec;64(12):1235-6. doi: 10.1007/s00228-008-0551-1. Epub 2008 Aug 20.

5

Review of atazanavir: a novel HIV protease inhibitor.

Expert Opin Pharmacother. 2005 Aug;6(9):1565-72. doi: 10.1517/14656566.6.9.1565.

6

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.阿扎那韦的临床药代动力学及疗效与耐受性总结

Clin Pharmacokinet. 2005;44(10):1035-50. doi: 10.2165/00003088-200544100-00003.

7

Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.阿扎那韦、沙奎那韦和利托那韦每日一次双重强化蛋白酶抑制剂方案的血浆水平、安全性及60周疗效

J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):127-9. doi: 10.1097/QAI.0b013e318157b0da.

8

Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Atazanavir--booster of the future?第四届HIV治疗临床药理学国际研讨会报告。阿扎那韦——未来的增效剂？

TreatmentUpdate. 2003 Apr-May;15(3):5-6.

9

Lack of interaction between atazanavir and lansoprazole.阿扎那韦与兰索拉唑之间无相互作用。

AIDS. 2005 Mar 24;19(6):637-8. doi: 10.1097/01.aids.0000163946.16435.50.

10

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.在HIV-1感染的成人中，联用替诺福韦不会损害利托那韦增强的阿扎那韦的稳态药代动力学。

Eur J Clin Pharmacol. 2007 Oct;63(10):935-40. doi: 10.1007/s00228-007-0344-y. Epub 2007 Jul 31.

引用本文的文献

1

Drug-drug interaction profiles of proton pump inhibitors.质子泵抑制剂的药物相互作用谱。

Clin Pharmacokinet. 2010 Aug;49(8):509-33. doi: 10.2165/11531320-000000000-00000.

2

Drug interactions between HIV protease inhibitors and acid-reducing agents.HIV蛋白酶抑制剂与抗酸剂之间的药物相互作用。

Clin Pharmacokinet. 2008;47(2):75-89. doi: 10.2165/00003088-200847020-00001.